TP53 and androgen insensitivity syndrome: Specifically, TP53 was detected in 1% of AAH/AIS/MIA samples but in 32% of LUAD samples, highlighting its critical role in disease progression from precursors to invasive tumors.37,38 In line with a previous study that involved 98 pre-invasive and 99 invasive LUADs, we found that TMB, APOBEC signature activity, WGD events, and SCNA burden all increased as tumors progressed from pre-invasive to invasive stages.22 Using WGS data, we were able to detect SVs, revealing that SVs were more prevalent at higher disease stages.